Patent · US Active

Combination of local temozolomide with local BCNU

US8895597B2 · kind B2 · utility

0Cited by

11References

8Claims

0Family size

Inventors

Violette Renard Recinos · Highland Heights, US
Betty M. Tyler · Baltimore, US
Sarah Brem Sunshine · Pikesville, US
Henry Brem · Baltimore, US

Key dates

Filing date	Jun 17, 2011
Grant date	Nov 25, 2014
Priority date	—
Expiry date	Oct 3, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The additive effect of combined intracranial carmustine (“BCNU”) with intracranial temozolomide (“TMZ”), and particularly in combination with radiation (“XRT”), in the treatment of two rat intracranial glioma models, the 9L gliosarcoma and the F98 glioma, demonstrates that local delivery of both drugs, especially in combination with radiation, is far more effective than delivery of either drug alone or one systemically and one locally, either with or without radiation. The triple therapy showed a significant improvement in survival when compared to controls (p=0.0004), local BCNU (p=0.0043), oral TMZ (p=0.0026), local TMZ (p=0.0105), and the combinations of either BCNU and XRT (p=0.0378) or oral TMZ and local BCNU (p=0.0154).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.